Celecoxib loses its anti-inflammatory efficacy at high doses through activation of NF-kappaB.

The FASEB journal : official publication of the Federation of American Societies for Experimental Biology

Volumn 15, Issue 9, 2001, Pages 1622-1624

  Niederberger, E ^a   Tegeder, I ^a   Vetter, G ^a   Schmidtko, A ^a   Schmidt, H ^a   Euchenhofer, C ^a   Brautigam L ^a   Grosch S ^a   Geisslinger, G ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; ISOENZYME; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PYRAZOLE DERIVATIVE; SULFONAMIDE; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; GENETIC TRANSCRIPTION; GENETICS; INFLAMMATION; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2; DINOPROSTONE; DISEASE MODELS, ANIMAL; INFLAMMATION; INTERLEUKIN-1; ISOENZYMES; MALE; NF-KAPPA B; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; TRANSCRIPTION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA; ZYMOSAN;

MLCS; MLOWN;

EID: 0035403764     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.00-0716fje     Document Type: Article

References (0)